Genomic characterization of an NDM-9-producing Acinetobacter baumannii clinical isolate and role of Glu152Lys substitution in the enhanced cefiderocol hydrolysis of NDM-9
- PMID: 37700870
- PMCID: PMC10493327
- DOI: 10.3389/fmicb.2023.1253160
Genomic characterization of an NDM-9-producing Acinetobacter baumannii clinical isolate and role of Glu152Lys substitution in the enhanced cefiderocol hydrolysis of NDM-9
Abstract
Here, we characterized the first French NDM-9-producing Acinetobacter baumannii isolate. A. baumannii 13A297, which belonged to the STPas25 (international clone IC7), was highly resistant to β-lactams including cefiderocol (MIC >32 mg/L). Whole genome sequencing (WGS) using both Illumina and Oxford Nanopore technologies revealed a 166-kb non-conjugative plasmid harboring a blaNDM-9 gene embedded in a Tn125 composite transposon. Complementation of E. coli DH5α and A. baumannii CIP70.10 strains with the pABEC plasmid carrying the blaNDM-1 or blaNDM-9 gene, respectively, resulted in a significant increase in cefiderocol MIC values (16 to >256-fold), particularly in the NDM-9 transformants. Interestingly, steady-state kinetic parameters, measured using purified NDM-1 and NDM-9 (Glu152Lys) enzymes, revealed that the affinity for cefiderocol was 3-fold higher for NDM-9 (Km = 53 μM) than for NDM-1 (Km = 161 μM), leading to a 2-fold increase in catalytic efficiency for NDM-9 (0.13 and 0.069 μM-1.s-1, for NDM-9 and NDM-1, respectively). Finally, we showed by molecular docking experiments that the residue 152 of NDM-like enzymes plays a key role in cefiderocol binding and resistance, by allowing a strong ionic interaction between the Lys152 residue of NDM-9 with both the Asp223 residue of NDM-9 and the carboxylate group of the R1 substituent of cefiderocol.
Keywords: Acinetobacter baumannii; NDM; carbapenemases; cefiderocol; resistance.
Copyright © 2023 Gaillot, Oueslati, Vuillemenot, Bour, Iorga, Triponney, Plésiat, Bonnin, Naas, Jeannot and Potron.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures


References
-
- Antimicrobial Resistance in the EU/EEA (EARS-Net) . (2022). Annual Epidemiological Report for 2021. Available at: https://www.ecdc.europa.eu/sites/default/files/documents/AER-EARS-Net-20...
-
- Clinical and Laboratory Standards Institute . (2020). Performance standards for antimicrobial susceptibility testing M100 S, 33th Edn; Clinical and Laboratory Standards Institute: Wayne, PA. 2023.
-
- da Silva K. E., Maciel W. G., Croda J., Cayô R., Ramos A. C., de Sales R. O., et al. . (2018). A high mortality rate associated with multidrug-resistant Acinetobacter baumannii ST79 and ST25 carrying OXA-23 in a Brazilian intensive care unit. PLoS One 13:e0209367. doi: 10.1371/journal.pone.0209367, PMID: - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources